Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach.

Madeddu C, Gramignano G, Astara G, Demontis R, Sanna E, Atzeni V, Macciò A.

Front Physiol. 2018 Sep 20;9:1294. doi: 10.3389/fphys.2018.01294. eCollection 2018. Review.

2.

Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: key role of interleukin-6.

Madeddu C, Gramignano G, Kotsonis P, Coghe F, Atzeni V, Scartozzi M, Macciò A.

Haematologica. 2018 Sep;103(9):e388-e391. doi: 10.3324/haematol.2018.191551. Epub 2018 Apr 19. No abstract available.

3.

Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.

Palomba G, Doneddu V, Cossu A, Paliogiannis P, Manca A, Casula M, Colombino M, Lanzillo A, Defraia E, Pazzola A, Sanna G, Putzu C, Ortu S, Scartozzi M, Ionta MT, Baldino G, Sarobba G, Capelli F, Sedda T, Virdis L, Barca M, Gramignano G, Budroni M, Tanda F, Palmieri G.

J Transl Med. 2016 Oct 13;14(1):292.

4.

Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches.

Madeddu C, Mantovani G, Gramignano G, Astara G, Macciò A.

Future Oncol. 2015 Oct;11(19):2697-2710. doi: 10.2217/fon.15.195. Epub 2015 Sep 17.

PMID:
26376740
5.

Advances in pharmacologic strategies for cancer cachexia.

Madeddu C, Mantovani G, Gramignano G, Macciò A.

Expert Opin Pharmacother. 2015;16(14):2163-77. doi: 10.1517/14656566.2015.1079621. Epub 2015 Sep 2. Review.

PMID:
26330024
6.

A Multitargeted Treatment Approach for Anemia and Cachexia in Metastatic Castration-Resistant Prostate Cancer.

Macciò A, Gramignano G, Madeddu C.

J Pain Symptom Manage. 2015 Aug;50(2):e1-4. doi: 10.1016/j.jpainsymman.2015.04.014. Epub 2015 May 21. No abstract available.

PMID:
26004402
7.

Surprising results of a supportive integrated therapy in myelofibrosis.

Macciò A, Gramignano G, Madeddu C.

Nutrition. 2015 Jan;31(1):239-43. doi: 10.1016/j.nut.2014.07.016. Epub 2014 Aug 6.

PMID:
25466670
8.

Role of inflammation and oxidative stress in post-menopausal oestrogen-dependent breast cancer.

Madeddu C, Gramignano G, Floris C, Murenu G, Sollai G, Macciò A.

J Cell Mol Med. 2014 Dec;18(12):2519-29. doi: 10.1111/jcmm.12413. Epub 2014 Oct 22.

9.

The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study.

Macciò A, Madeddu C, Gramignano G, Mulas C, Tanca L, Cherchi MC, Floris C, Omoto I, Barracca A, Ganz T.

Haematologica. 2015 Jan;100(1):124-32. doi: 10.3324/haematol.2014.112813. Epub 2014 Sep 19.

10.

Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer: A report of two cases.

Madeddu C, Gramignano G, Kotsonis P, Paribello F, Macciò A.

Oncol Lett. 2014 Sep;8(3):1279-1282. Epub 2014 Jul 4.

11.

A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life.

Macciò A, Madeddu C, Gramignano G, Mulas C, Floris C, Sanna E, Cau MC, Panzone F, Mantovani G.

Gynecol Oncol. 2012 Mar;124(3):417-25. doi: 10.1016/j.ygyno.2011.12.435. Epub 2011 Dec 20.

PMID:
22198049
12.

Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study.

Macciò A, Madeddu C, Gramignano G, Mulas C, Sanna E, Mantovani G.

Oncologist. 2010;15(8):894-902. doi: 10.1634/theoncologist.2010-0020. Epub 2010 Jul 20.

13.

Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications.

Macciò A, Madeddu C, Gramignano G, Mulas C, Floris C, Massa D, Astara G, Chessa P, Mantovani G.

J Mol Med (Berl). 2010 Jul;88(7):677-86. doi: 10.1007/s00109-010-0611-8. Epub 2010 Mar 26.

PMID:
20339829
14.

An Innovative Treatment Approach for Cancer-Related Anorexia/Cachexia and Oxidative Stress: Background and Design of an Ongoing, Phase III, Randomized Clinical Trial.

Mantovani G, Madeddu C, Gramignano G, Serpe R, Massa E, Deiana L, Macciò A.

Support Cancer Ther. 2007 May 1;4(3):163-7. doi: 10.3816/SCT.2007.n.011. No abstract available.

PMID:
18632483
15.

Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results.

Mantovani G, Macciò A, Madeddu C, Gramignano G, Serpe R, Massa E, Dessì M, Tanca FM, Sanna E, Deiana L, Panzone F, Contu P, Floris C.

Nutrition. 2008 Apr;24(4):305-13. doi: 10.1016/j.nut.2007.12.010. Epub 2008 Feb 11.

PMID:
18262758
16.
17.

Use of chemotherapy for ovarian cancer during human pregnancy: case report and literature review.

Mantovani G, Gramignano G, Mais V, Melis GB, Parodo G, Carrucciu GM.

Eur J Obstet Gynecol Reprod Biol. 2007 Apr;131(2):238-9. Epub 2006 May 12. Review. No abstract available.

PMID:
16698170
18.

Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy.

Gramignano G, Lusso MR, Madeddu C, Massa E, Serpe R, Deiana L, Lamonica G, Dessì M, Spiga C, Astara G, Macciò A, Mantovani G.

Nutrition. 2006 Feb;22(2):136-45.

PMID:
16459226
20.

Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia.

Macciò A, Madeddu C, Massa D, Mudu MC, Lusso MR, Gramignano G, Serpe R, Melis GB, Mantovani G.

Blood. 2005 Jul 1;106(1):362-7. Epub 2005 Mar 17.

21.

Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment.

Mantovani G, Madeddu C, Macciò A, Gramignano G, Lusso MR, Massa E, Astara G, Serpe R.

Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1651-9.

22.

Selenium is effective in inducing lymphocyte progression through cell cycle in cancer patients: potential mechanisms for its activity.

Mantovani G, Macciò A, Madeddu C, Serpe R, Massa E, Gramignano G, Lusso MR, Curreli N, Rinaldi A.

J Exp Ther Oncol. 2004 Apr;4(1):69-78.

PMID:
15255293
23.

Association of serum IL-6 levels with comprehensive geriatric assessment variables in a population of elderly cancer patients.

Mantovani G, Madeddu C, Gramignano G, Ferreli L, Massa E, Contu P, Serpe R.

Oncol Rep. 2004 Jan;11(1):197-206.

PMID:
14654926
24.

Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters.

Mantovani G, Madeddu C, Gramignano G, Lusso MR, Mocci M, Massa E, Ferreli L, Astara G, Macciò A, Serpe R.

J Exp Ther Oncol. 2003 Jul-Aug;3(4):205-19.

PMID:
14567291
25.

Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress.

Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR, Massa E, Mocci M, Serpe R.

J Mol Med (Berl). 2003 Oct;81(10):664-73. Epub 2003 Aug 19.

PMID:
12928788
26.

Six-week induction chemotherapy followed by concomitant chemoradiation therapy in stage IV head and neck cancer: a phase II study with organ-sparing purposes.

Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Ferreli L, Camboni P, Lusso MR, Mocci M, Madeddu C, Mura L, Mudu MC, Proto E, Tore G, Mura M, Macciò A, Ferreli A, Amichetti M.

Oncol Rep. 2003 May-Jun;10(3):759-66.

PMID:
12684655
27.

Reactive oxygen species, antioxidant mechanisms, and serum cytokine levels in cancer patients: impact of an antioxidant treatment.

Mantovani G, Macciò A, Madeddu C, Mura L, Massa E, Gramignano G, Lusso MR, Murgia V, Camboni P, Ferreli L.

J Environ Pathol Toxicol Oncol. 2003;22(1):17-28.

PMID:
12678402
28.

The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression.

Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR, Murgia V, Camboni P, Ferreli L, Mocci M, Massa E.

Free Radic Res. 2003 Feb;37(2):213-23.

PMID:
12653210
29.

Reactive oxygen species, antioxidant mechanisms and serum cytokine levels in cancer patients: impact of an antioxidant treatment.

Mantovani G, Macciò A, Madeddu C, Mura L, Massa E, Gramignano G, Lusso MR, Murgia V, Camboni P, Ferreli L.

J Cell Mol Med. 2002 Oct-Dec;6(4):570-82.

30.

Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs.

Mantovani G, Massa E, Astara G, Murgia V, Gramignano G, Lusso MR, Camboni P, Ferreli L, Mocci M, Perboni S, Mura L, Madeddu C, Macciò A.

Oncol Rep. 2003 Jan-Feb;10(1):197-206.

PMID:
12469169
31.

Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy.

Mantovani G, Macciò A, Madeddu C, Mulas C, Massa E, Astara G, Ferreli L, Mudu MC, Gramignano G, Murgia V, Lusso MR, Mocci M, Cardia A, Mura L.

Oncol Rep. 2002 Jul-Aug;9(4):887-96.

PMID:
12066227
32.

Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status.

Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR, Mulas C, Mudu MC, Murgia V, Camboni P, Massa E, Ferreli L, Contu P, Rinaldi A, Sanjust E, Atzei D, Elsener B.

Int J Cancer. 2002 Mar 1;98(1):84-91.

33.

Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity.

Mantovani G, Proto E, Massa E, Mulas C, Madeddu C, Mura L, Mudu MC, Astara G, Murgia V, Gramignano G, Ferreli L, Camboni P, Lusso MR, Mocci M, Tore G, Mura M, Amichetti M, Maccio A.

Int J Oncol. 2002 Feb;20(2):419-27.

PMID:
11788911
34.

Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites.

Mantovani G, Macciò A, Madeddu C, Mura L, Massa E, Mudu MC, Mulas C, Lusso MR, Gramignano G, Piras MB.

J Mol Med (Berl). 2001 Jul;79(7):406-14.

PMID:
11466563
35.

Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy.

Mantovani G, Maccio A, Madeddu C, Massa E, Mudu MC, Mulas C, Gramignano G, Massidda S, Murgia V, Lusso MR, Mura L.

Int J Oncol. 2001 Feb;18(2):383-91.

PMID:
11172608

Supplemental Content

Loading ...
Support Center